Literature DB >> 35320541

Examining the Impact of Galectin-9 on Latent HIV Transcription.

Opeyemi S Adeniji1, Leila B Giron1, Mohamed Abdel-Mohsen2,3.   

Abstract

The β-galactoside-binding protein Galectin-9 (Gal-9) functions as a double-edged sword during HIV infection. On the one hand, Gal-9 can reactivate HIV latently infected cells, the main barrier to achieving HIV eradication, making them visible to immune clearance. On the other hand, Gal-9 induces latent HIV transcription by activating T cell Receptor (TCR) signaling pathways. These signaling pathways induce undesirable pro-inflammatory responses. While these unwanted responses can be mitigated by rapamycin without impacting Gal-9-mediated latent HIV reactivation, this effect raises the concern that Gal-9 may play a role in the chronic immune activation/inflammation that persists in people living with HIV despite antiretroviral therapy. Together, these data highlight the need to understand the positive and negative impacts of galectin interactions on immunological functions during HIV infection. In this chapter, we describe methods that can be used to investigate the effects of galectins, in particular Gal-9, on latent HIV transcription in vitro and ex vivo.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Galectin-9; Galectins; HIV; HIV persistence; J-Lat cell line; Latent HIV transcription

Mesh:

Substances:

Year:  2022        PMID: 35320541     DOI: 10.1007/978-1-0716-2055-7_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

1.  Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell-cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells.

Authors:  Julio Cesar Madureira de Freitas Junior; Bárbara Du Rocher D'Aguiar Silva; Waldemir Fernandes de Souza; Wallace Martins de Araújo; Eliana Saul Furquim Werneck Abdelhay; José Andrés Morgado-Díaz
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-07       Impact factor: 3.333

Review 2.  Targeting glycosylation as a therapeutic approach.

Authors:  Raymond A Dwek; Terry D Butters; Frances M Platt; Nicole Zitzmann
Journal:  Nat Rev Drug Discov       Date:  2002-01       Impact factor: 84.694

Review 3.  Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis.

Authors:  Santiago P Méndez-Huergo; Ada G Blidner; Gabriel A Rabinovich
Journal:  Curr Opin Immunol       Date:  2017-01-11       Impact factor: 7.486

Review 4.  Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function.

Authors:  Ya Zhuo; Susan L Bellis
Journal:  J Biol Chem       Date:  2010-12-20       Impact factor: 5.157

5.  Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.

Authors:  Logan K Smith; Giselle M Boukhaled; Stephanie A Condotta; Sabrina Mazouz; Jenna J Guthmiller; Rahul Vijay; Noah S Butler; Julie Bruneau; Naglaa H Shoukry; Connie M Krawczyk; Martin J Richer
Journal:  Immunity       Date:  2018-01-23       Impact factor: 31.745

6.  Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response.

Authors:  Sharvan Sehrawat; Pradeep B J Reddy; Naveen Rajasagi; Amol Suryawanshi; Mitsuomi Hirashima; Barry T Rouse
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

7.  Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.

Authors:  Alison J Rodger; Rebecca Lodwick; Mauro Schechter; Steven Deeks; Janaki Amin; Richard Gilson; Roger Paredes; Elzbieta Bakowska; Frederik N Engsig; Andrew Phillips
Journal:  AIDS       Date:  2013-03-27       Impact factor: 4.177

Review 8.  Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population.

Authors:  Gilles Wandeler; Leigh F Johnson; Matthias Egger
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

9.  Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.

Authors:  Ravi Tandon; Glen M Chew; Mary M Byron; Persephone Borrow; Toshiro Niki; Mitsuomi Hirashima; Jason D Barbour; Philip J Norris; Marion C Lanteri; Jeffrey N Martin; Steven G Deeks; Lishomwa C Ndhlovu
Journal:  AIDS Res Hum Retroviruses       Date:  2014-05-28       Impact factor: 2.205

10.  Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.

Authors:  Monica Gordon-Alonso; Thibault Hirsch; Claude Wildmann; Pierre van der Bruggen
Journal:  Nat Commun       Date:  2017-10-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.